PI4K2B (phosphatidylinositol 4-kinase type 2 beta) is a membrane-associated enzyme that catalyzes phosphorylation of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P), contributing to the overall phosphoinositide signaling capacity of the cell alongside PI4K2A and type III PI4Ks 12. This enzymatic activity is particularly significant in plasma membrane, endosomal, and Golgi compartments 12. PI4P serves as a precursor for phosphatidylinositol 4,5-bisphosphate (PIP2) and inositol 1,4,5-trisphosphate (InsP3), critical second messengers involved in cellular signaling and vesicular trafficking 12. Unlike the structurally similar PI4K2A isoform, PI4K2B lacks a GABARAP-binding motif in its catalytic domain, limiting its role in autophagosome-lysosome fusion 3. Regarding disease relevance, PI4K2B has been associated with cannabis use disorder in genome-wide association studies 4 and identified as part of a gene-by-sleepiness interaction network in sleep apnea pathogenesis 5. Additionally, PI4K2B has emerged as a minor histocompatibility antigen target in graft-versus-leukemia responses 6 and as a component of a prognostic model for cisplatin resistance in small cell lung cancer 7. While PI4K2B was investigated as a candidate gene in bipolar disorder linkage studies, no definitive evidence supported its contribution to this condition 8.